Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Tatyana B. Prigozhina"'
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Cytotoxic T-lymphocyte antigen 4 (CTLA4)-FasL, a homo-hexameric signal converter protein, is capable of inducing robust apoptosis in malignant cells of the B-cell lineage expressing its cognate B7 and Fas targets, while sparing nonmalignant ones. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8acdcf063baf664e37a78b4888b1cb1
https://doi.org/10.1158/1535-7163.c.6542272.v1
https://doi.org/10.1158/1535-7163.c.6542272.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
(a) Receptors expression on human cell lines and mouse BCL-1 splenocytes. (b) Anti CTLA4-FasL antibodies are formed in treated mice. (c) Neutralizing anti CTLA4-FasL antibodies are formed in treated mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b964846c2e67de8d26eac159f86a21bb
https://doi.org/10.1158/1535-7163.22519081.v1
https://doi.org/10.1158/1535-7163.22519081.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Table S1. Summary of the Toxicokinetic Parameters of CTLA4-FasL in mouse Plasma at the first injection (Day 1) and the third injection (Day 5) Table S2. Summary of the Pharmacokinetic parameters in a single dose of CTLA4-FasL in Cynomolgus monkey pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c90efa3cfd76a11505c99d79171c4e
https://doi.org/10.1158/1535-7163.22519057.v1
https://doi.org/10.1158/1535-7163.22519057.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1700b3bdd4de82a3cc3d1d6b0fa0dc1e
https://doi.org/10.1158/1535-7163.22519060.v1
https://doi.org/10.1158/1535-7163.22519060.v1
Autor:
Alexandra Aronin, Shira Amsili, Tatyana B Prigozhina, Kobi Tzdaka, Jacob Rachmilewitz, Noam Shani, Mark L Tykocinski, Michal Dranitzki Elhalel
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77050 (2013)
BACKGROUND:New strategies for the treatment of hepatocellular carcinoma (HCC) are needed, given that currently available chemotherapeutics are inefficient. Since tumor growth reflects the net balance between pro-proliferative and death signaling, age
Externí odkaz:
https://doaj.org/article/2abdbdcf2b784c789083154a29afa674
Autor:
Alexandra Aronin, Shira Amsili, Yosi Gozlan, Liat Ben Gigi Tamir, Jitka Yehudith Sagiv, Fanny Shkedy, Tatyana B. Prigozhina, Michal Dranitzki Elhalel, Noam Shani, Efi Makdasi, Kobi Tzdaka, Mark L. Tykocinski
Publikováno v:
Molecular cancer therapeutics. 19(2)
Cytotoxic T-lymphocyte antigen 4 (CTLA4)-FasL, a homo-hexameric signal converter protein, is capable of inducing robust apoptosis in malignant cells of the B-cell lineage expressing its cognate B7 and Fas targets, while sparing nonmalignant ones. Thi
Autor:
Efi Makdasi, Michal Dranitzki Elhalel, Kobi Tzdaka, Fanny Szafer, Alexandra Aronin, Noam Shani, Tatyana B. Prigozhina, Shira Amsili
Publikováno v:
Cancer letters. 400
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) demonstrates specific anti-cancer activity, but insufficient efficacy in patients. A fusion protein Fn14·TRAIL, that combines soluble TRAIL molecule with a specific TWEAK receptor Fn14,
Publikováno v:
Biology of Blood and Marrow Transplantation. 18(4):523-535
T cell depletion prevents graft-versus-host disease (GVHD) but also removes T cell-mediated support of hematopoietic cell engraftment. A chimeric molecule composed of IL-2 and caspase-3 (IL2-cas) has been evaluated as a therapeutic modality for GVHD
Publikováno v:
Experimental Hematology. 36:1750-1759
Objective Previously, we documented that conditioning based on donor-specific cell transfusion (DST) and subsequent selective depletion of activated donor-reactive cells by cyclophosphamide (CY) facilitates alloengraftment in a murine transplantation
Publikováno v:
Transplantation Proceedings. 39:678-684
Progress in the development of less toxic conditioning for bone marrow transplantation (BMT) came with the understanding that acceptance of mismatched BM does not require myeloablation of recipients. Lymphocyte deletion by a cocktail of immunosuppres